Always On Authentication™

We are an enterprise authentication solution for increased security and productivity across pharmaceutical manufacturing. 

Nymi Enterprise Edition™ delivers secure authentication solutions to pharmaceutical manufacturing environments. We replace existing point-in-time authentication models often used in manufacturing settings with one that sees its users in a continuously authenticated state throughout their workday.


Click the icons to the right for more information.

Visit nymi.com to learn more about our solution.

Security

Productivity

Compliance

Nymi™’s Enterprise Security Solution combines the security of biometrics with a convenient wearable device that addresses critical business needs for data integrity and productivity.


The Nymi Band™ is an innovative, wearable authentication device that allows an enterprise and its regulators’ full knowledge of who has access to facilities, equipment, and applications. 
Multi-factor biometric authentication ensures each Nymi Band™ only works while on the wrist of an approved operator, and once
authenticated, cannot be transferred.

Employee Log Ins

Tap with Nymi Band™

Typing username 
and password

repeat

100x

daily

Secure, non-repudiable, wireless taps of the Nymi Band™ make cumbersome repetitive tasks, like typing passwords and paper signatures a thing of the past. 


With Nymi Enterprise Edition™, logins are replaced with a single action that takes merely a few seconds. The time saved by reducing login times and removing user authentication errors (failed usernames and passwords) leads to dramatic increases in efficiency for manufacturing environments.

Nymi™’s authentication technologies provide data integrity that assures compliance with standards such as the US Food and Drug Administration (FDA) CFR Part 11. 


Nymi Enterprise Edition™ is able to assure the integrity of the data being produced on the floor through a combination of biometrics, on-body detection, and strong industry-standard cryptography.
It also provides real-time, on demand traceability and non-repudiable electronic records, which makes simpler, less intrusive audits a reality.

Go to article: Home | The absence of antivenomGo to article: In this issueGo to article: Daiichi JitsugyoGo to article: ContentsGo to article: Capsugel Company InsightGo to article: CapsugelGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: The pharma industry briefingGo to article: TSS Company InsightGo to article: TSS ABGo to article: Action Medical Research: celebrating decades of discovery Go to article: Swiss WorldCargoGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Moehs Iberica SLGo to article: Owen MumfordGo to article: How government policy has shaped China’s pharma phenomenonGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Novo NordiskGo to article: Snake venom in pharma; access to antivenom is a topic that needs attentionGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: ME Logistic ServicesGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Aseptic TechnologiesGo to article: False flags: are search engines benefiting rogue online pharmacies?Go to article: CBDepot Company InsightGo to article: CBDepotGo to article: Wilco Company Insight Go to article: WilcoGo to article: The Mighty: how patients and pharma align in the age of social media Go to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: MicronovaGo to article: Inside Italy’s pharmaceutical industry Go to article: KlingeGo to article: BEAGo to article: Erdmann Design SwitzerlandGo to article: Inside the UK’s first vaccines innovation centreGo to article: AralabGo to article: Applikon BiotechnologyGo to article: BaxterGo to article: NymiGo to article: Fostering closer collaboration between manufacturing & regulatory functionsGo to article: EmisphereGo to article: SephaGo to article: Contract Pharmaceuticals Limited CanadaGo to article: EventsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Next issueGo to article: PolpharmaGo to article: BioAdvice